drugset / Trial / NCT05317819
Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma
RandomizedParallel-groupTriple-blindTreatment
Summary
Evaluate efficacy and safety of ADI-PEG 20 in patients with high-argininephenotypic and HCC
Timeline
- Start
- 2022-03-14
- Primary completion
- 2028-09
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegargiminase | Protein / enzyme biologic | 36 mg/m2 | Intramuscular |